Capital Research Global Investors Teva Pharmaceutical Industries LTD Transaction History

Capital Research Global Investors

$443 Billion
Q2 2024

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$8.36 - $11.37 $269 Million - $366 Million	-32,149,622 Reduced 28.01%	82,644,367 $731 Million
Q4 2022 Feb 14, 2023	SELL	$7.95 - $9.48 $19.1 Million - $22.7 Million	-2,396,339 Reduced 2.04%	114,793,989 $1.05 Billion
Q3 2022 Nov 14, 2022	BUY	$6.86 - $11.95 $165 Million - $287 Million	24,024,045 Added 25.79%	117,190,328 $946 Million
Q2 2022 Aug 15, 2022	SELL	$7.38 - $10.4 $288 Million - $406 Million	-38,999,232 Reduced 29.51%	93,166,283 $701 Million
Q1 2022 May 16, 2022	SELL	$7.33 - $9.39 $1.36 Million - $1.74 Million	-185,235 Reduced 0.14%	132,165,515 $1.24 Billion
Q4 2021 Feb 14, 2022	BUY	$7.9 - $10.19 $106 Million - $137 Million	13,474,099 Added 11.33%	132,350,750 $1.06 Billion
Q3 2021 Nov 15, 2021	SELL	$8.38 - $10.18 $31.6 Million - $38.4 Million	-3,775,923 Reduced 3.08%	118,876,651 $1.16 Billion
Q2 2021 Aug 16, 2021	SELL	$9.9 - $11.56 $59.8 Million - $69.8 Million	-6,040,649 Reduced 4.69%	122,652,574 $1.21 Billion
Q1 2021 May 14, 2021	SELL	$10.34 - $12.81 $15 Million - $18.5 Million	-1,447,024 Reduced 1.11%	128,693,223 $1.49 Billion
Q4 2020 Feb 12, 2021	BUY	$8.61 - $11.04 $282,218 - $361,869	32,778 Added 0.03%	130,140,247 $1.26 Billion
Q3 2020 Nov 13, 2020	SELL	$8.57 - $12.69 $175,479 - $259,840	-20,476 Reduced 0.02%	130,107,469 $1.17 Billion
Q2 2020 Aug 14, 2020	BUY	$8.12 - $13.12 $301,609 - $487,329	37,144 Added 0.03%	130,127,945 $1.6 Billion
Q1 2020 May 15, 2020	SELL	$6.69 - $13.45 $5.75 Million - $11.6 Million	-859,876 Reduced 0.66%	130,090,801 $1.17 Billion
Q4 2019 Feb 18, 2020	BUY	$6.53 - $10.72 $138,762 - $227,800	21,250 Added 0.02%	130,950,677 $1.28 Billion
Q3 2019 Nov 14, 2019	BUY	$6.16 - $9.6 $229,139 - $357,100	37,198 Added 0.03%	130,929,427 $901 Million
Q2 2019 Aug 14, 2019	BUY	$8.12 - $15.72 $21.9 Million - $42.5 Million	2,700,837 Added 2.11%	130,892,229 $1.21 Billion
Q1 2019 May 15, 2019	BUY	$15.58 - $20.01 $97.2 Million - $125 Million	6,237,109 Added 5.11%	128,191,392 $2.01 Billion
Q4 2018 Feb 14, 2019	BUY	$14.59 - $23.84 $45.3 Million - $74 Million	3,105,683 Added 2.61%	121,954,283 $1.88 Billion
Q3 2018 Nov 14, 2018	SELL	$21.06 - $25.65 $67.1 Million - $81.7 Million	-3,184,236 Reduced 2.61%	118,848,600 $2.56 Billion
Q2 2018 Aug 14, 2018	BUY	$16.77 - $24.71 $6.1 Million - $8.99 Million	363,631 Added 0.3%	122,032,836 $2.97 Billion
Q1 2018 May 15, 2018	BUY	$16.68 - $22.07 $382 Million - $506 Million	22,916,493 Added 23.21%	121,669,205 $2.08 Billion
Q4 2017 Feb 14, 2018	BUY	$11.23 - $19.1 $322 Million - $547 Million	28,656,135 Added 40.88%	98,752,712 $1.87 Billion
Q3 2017 Nov 14, 2017	BUY	$15.41 - $32.17 $1.08 Billion - $2.26 Billion	70,096,577	70,096,577 $1.23 Billion

Others Institutions Holding TEVA

# of Institutions

617

Shares Held

563M

Call Options Held

25.2M

Put Options Held

5.08M

Black Rock Inc. New York, NY

43M
Shares

$752 Million
0.02% of portfolio
Ion Asset Management Ltd. George Town, Grand Cayman, E9

36.3M
Shares

$636 Million
41.14% of portfolio
Clal Insurance Enterprises Holdings LTD Tel Aviv, L3

32.3M
Shares

$566 Million
5.5% of portfolio
Menora Mivtachim Holdings Ltd.

28.8M
Shares

$505 Million
3.23% of portfolio
Exor Capital LLP London, X0

26.5M
Shares

$463 Million
15.49% of portfolio

View Full List

About TEVA PHARMACEUTICAL INDUSTRIES LTD

Ticker TEVA
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 1,110,560,000
Market Cap $19.4B
Description
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage form...

More about TEVA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Capital Research Global Investors, based on Form 13F filings with the SEC.

News

Stay updated on Capital Research Global Investors with notifications on news.

Account